Neuro-Oncology News

In a company release, Accuray Inc. announced its CyberKnife radiotherapy platform, which delivers stereotactic radiosurgery to treat lesions in the brain, was supported by more than 2 decades of globally driven clinical data.

Researchers reported common causes of death and end-of-life care experiences among patients with intracranial high-grade gliomas in a retrospective observational study published in Neurology.

Results of early clinical trials suggest that chimeric antigen receptor T cells can be adapted successfully to target brain tumors, according to a presenter at AACR Virtual Special Conference: Brain Cancer.

Patients with isocitrate dehydrogenase wild-type glioblastoma who used levetiracetam for the duration of chemoradiation may have a higher overall survival rate, according to an observational, retrospective cohort study in Neurology.

The National Academy of Medicine announced the election of 90 regular members and 10 international members.

Oren J. Becher, MD, has been appointed chief of the Jack Martin division of pediatric hematology-oncology at Mount Sinai Kravis Children’s Hospital.

The FDA awarded 11 grants worth more than $25 million to fund clinical trials of medical products intended to treat patients with rare diseases.

Higher tissue 2-hydroxyglutarate concentration appeared to increase risk for preoperative seizures in isocitrate dehydrogenase 1/2 mutant tumors, according to study results published in Neurology.

The FDA granted breakthrough device designation to Alpha DaRT for treatment of recurrent glioblastoma multiforme.

Brain and central nervous system tumors are the second most common malignancy among children and the most prevalent form of solid tumor, according to American Cancer Society data.